---
schema_version: "secwatch.filing_event.v1"
accession: "0001801170-24-000089"
form_type: "8-K"
ticker: "CLOV"
cik: "0001801170"
company_name: "CLOVER HEALTH INVESTMENTS, CORP. /DE"
filed_at: "2024-04-22T23:59:59+00:00"
generated_at: "2026-06-03T14:16:07.291633+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Clover Health names Peter Kuipers as CFO; targets adjusted EBITDA profitability in 2024

## Summary
- Peter Kuipers appointed CFO effective after Q1 2024 10-Q filing; succeeds interim CFO Terrence Ronan.
- Kuipers previously CFO at Omnicell (OMCL), helped grow revenue from $485M to $1.3B.
- Employment terms: base salary $525k, target bonus 95% of base, $5M RSU grant (25% vest 1yr, remainder quarterly).
- Company reiterates goal to achieve adjusted EBITDA profitability in 2024.

## SEC filing metadata
- accession: 0001801170-24-000089
- form_type: 8-K
- ticker: CLOV
- cik: 0001801170
- company_name: CLOVER HEALTH INVESTMENTS, CORP. /DE
- filed_at: 2024-04-22T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1801170/000180117024000089/0001801170-24-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1801170/000180117024000089/clov-20240422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001801170-24-000089
- JSON: https://secwatch.observer/filing/0001801170-24-000089.json
- Plain text: https://secwatch.observer/filing/0001801170-24-000089.txt

## Key facts
- Executive change
  Peter Kuipers was appointed as Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On April 22, 2024, Clover Health Investments, Corp. (the “Company”) announced that Peter Kuipers will become Chief Financial Officer of the Company, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the day after the filing of the Company’s Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024, as approved by the Board of Directors of the Company on April 16, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1801170/000180117024000089/0001801170-24-000089-index.htm
- Executive change
  Terrence Ronan departed as Interim Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
  - Action: cease to serve
  - Role: Interim Chief Financial Officer
  source text: Mr. Kuipers will succeed Terrence Ronan, the Company’s current Interim Chief Financial Officer, who will continue in his role as Interim Chief Financial Officer until Mr. Kuipers becomes Chief Financial Officer, and thereafter cease to serve as the Company’s principal financial officer and principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1801170/000180117024000089/0001801170-24-000089-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.